Engine Biosciences raises $57m in oversubscribed series A funding round

It's the largest ever for a biotech firm in Singapore.

Biotech firm Engine Biosciences has raised $57m after efficiently competing an outsized Collection A funding spherical.

This spherical was led by Polaris Companions and in addition included new buyers Invus and one of many world’s premier institutional buyers, primarily based in Singapore. Current buyers additionally participated within the Collection A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio.

“We are honored that this preeminent group of life science and technology investors has recognized the progress our team has made and is supporting our mission to unleash new medicines by deciphering biology,” stated Jeffrey Lu, Engine Biosciences’ Co-Founder and chief government officer.

Engine has already been progressing its novel biology findings into drug discovery applications and proprietary small molecule inhibitors. It would make the most of the brand new funds to develop its portfolio of precision oncology therapeutics, put together for its first medical applications, and scale its proprietary expertise platform.

Engine Biosciences is a venture-backed Singapore- and Silicon Valley-based firm deciphering complicated biology to unleash many impactful medicines.